Arcturus Therapeutics (ARCT) to Release Earnings on Thursday

Arcturus Therapeutics (NASDAQ:ARCT) will be announcing its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.70) per share for the quarter.

Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. The firm had revenue of $49.86 million during the quarter, compared to the consensus estimate of $21.00 million. During the same period in the prior year, the firm earned ($1.98) EPS. On average, analysts expect Arcturus Therapeutics to post $-3 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Arcturus Therapeutics Stock Performance

ARCT stock traded up $0.42 during midday trading on Friday, reaching $18.15. 12,952 shares of the company’s stock traded hands, compared to its average volume of 466,329. Arcturus Therapeutics has a 52 week low of $17.52 and a 52 week high of $45.00. The firm has a market capitalization of $488.78 million, a PE ratio of -6.90 and a beta of 2.61. The company has a 50-day moving average price of $20.94 and a two-hundred day moving average price of $24.64.

Insider Activity

In related news, COO Pad Chivukula sold 12,000 shares of Arcturus Therapeutics stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total transaction of $249,120.00. Following the completion of the transaction, the chief operating officer now directly owns 435,334 shares of the company’s stock, valued at $9,037,533.84. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 15.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ARCT shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Leerink Partners assumed coverage on Arcturus Therapeutics in a research note on Monday, August 12th. They set an “outperform” rating and a $70.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a research note on Tuesday, October 1st. Finally, Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a report on Monday, August 12th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $71.40.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.